期刊
CURRENT OPINION IN CHEMICAL BIOLOGY
卷 14, 期 4, 页码 467-474出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cbpa.2010.06.176
关键词
-
资金
- Northeast Biodefense Center [AI057158]
- Rocky Mountain Regional Center of Excellence [AI065357]
- National Institutes of Health [AI044639, AI070383]
Failure due to poor in vivo efficacy is a primary contributor to attrition during the development of new chemotherapeutics. Lead optimization programs that in their quest for efficacy focus solely on improving the affinity of drug-target binding are flawed, since this approach ignores the fluctuations in drug concentration that occur in vivo. Instead the lifetime of the drug-target complex must also be considered, since drugs only act when they are bound to their targets. Consequently, to improve the correlation between the in vitro and in vivo activity of drugs, measurements of drug-target residence time must be incorporated into the drug discovery process.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据